跳至主要内容
临床试验/NCT07665957
NCT07665957尚未招募不适用

Comparative Effectiveness of Multiple Micronutrient Supplementation (MMS), Iron-Folic Acid (IFA), and Combined MMS+IFA on Maternal Hemoglobin Levels and Neonatal Outcomes Among Pregnant Women: An Open-Label Randomized Controlled Trial

Sindh Institute of Child Health and Neonatology0 个研究点目标入组 402 人开始时间: 2026年6月25日最近更新:
干预措施

试验速览

阶段
不适用
状态
尚未招募
入组人数
402

研究概览

简要总结

This study aims to compare the effectiveness of Multiple Micronutrient Supplementation (MMS), Iron-Folic Acid (IFA) supplementation, and combined MMS+IFA supplementation among pregnant women. Maternal anemia and micronutrient deficiencies are common during pregnancy and can adversely affect both maternal and neonatal health outcomes.

A total of 402 pregnant women with gestational age of 20 weeks or less will be randomly assigned to receive MMS, IFA, or combined MMS+IFA supplementation. Participants will be followed throughout pregnancy until delivery. Maternal hemoglobin levels, maternal compliance with supplementation, and neonatal outcomes including birth weight, preterm birth, APGAR scores, and congenital anomalies will be assessed.

The findings of this study will provide evidence to guide antenatal nutrition policies and practices in Pakistan.

详细描述

Maternal micronutrient deficiencies remain a major public health concern in low- and middle-income countries, including Pakistan. Iron deficiency anemia, along with deficiencies of folate, vitamin D, vitamin B12, zinc, iodine, and other micronutrients, contributes substantially to adverse maternal and neonatal outcomes. Although routine Iron-Folic Acid (IFA) supplementation is recommended during pregnancy, it may not adequately address the broader spectrum of micronutrient deficiencies commonly observed among pregnant women.

Multiple Micronutrient Supplementation (MMS) has emerged as a comprehensive alternative that includes iron, folic acid, and additional essential vitamins and minerals required during pregnancy. Evidence from randomized controlled trials and systematic reviews suggests that MMS may improve selected neonatal outcomes; however, evidence regarding maternal hemoglobin improvement and compliance remains inconsistent across settings. Furthermore, limited data are available from Pakistan comparing MMS, IFA, and combined MMS+IFA supplementation.

This study is a three-arm, parallel-group, open-label randomized controlled trial conducted at the antenatal clinics of the Sindh Institute of Child Health and Neonatology (SICHN) in Karachi and Jamshoro, Pakistan. A total of 402 eligible pregnant women with gestational age ≤20 weeks and baseline hemoglobin ≥10 g/dL will be enrolled and randomized in a 1:1:1 ratio to receive either MMS, IFA, or combined MMS+IFA supplementation.

Maternal hemoglobin concentration will be measured at baseline, 28 weeks gestation, and 36-37 weeks gestation or delivery. Maternal compliance will be assessed using pill counts and self-reported supplement intake. Neonatal outcomes including birth weight, low birth weight, preterm birth, APGAR scores, and congenital anomalies will be evaluated at delivery.

The study aims to compare the effectiveness of MMS, IFA, and MMS+IFA supplementation on maternal hemoglobin levels, neonatal outcomes, and maternal compliance. Findings from this study will contribute to strengthening evidence-based antenatal nutrition policies and maternal health programs in Pakistan.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Pregnant women aged 18 years or older
  • Gestational age ≤20 weeks at enrollment
  • Singleton pregnancy
  • Hemoglobin concentration ≥10 g/dL at baseline
  • Willing and able to provide informed consent
  • Willing to comply with study procedures and follow-up visits

排除标准

  • Severe anemia requiring injectable treatment (hemoglobin <7 g/dL)
  • Pre-existing diabetes mellitus
  • Pre-existing hypertension
  • Renal disease
  • Current therapeutic iron or micronutrient supplementation beyond routine antenatal supplementation
  • Known fetal congenital anomalies
  • Any medical condition that, in the opinion of the investigator, would interfere with study participation or outcome assessment

研究组 & 干预措施

MMS + IFA

Experimental

Combined Multiple Micronutrient Supplementation (MMS) and Iron-Folic Acid (IFA) supplementation administered daily during pregnancy. Total iron and folic acid intake will remain within safe WHO-recommended limits

干预措施: Multiple Micronutrient Supplementation (MMS) (Dietary Supplement)

MMS + IFA

Experimental

Combined Multiple Micronutrient Supplementation (MMS) and Iron-Folic Acid (IFA) supplementation administered daily during pregnancy. Total iron and folic acid intake will remain within safe WHO-recommended limits

干预措施: Iron-Folic Acid (IFA) (Dietary Supplement)

IFA

Active Comparator

干预措施: Iron-Folic Acid (IFA) (Dietary Supplement)

MMS

Experimental

Multiple Micronutrient Supplementation (MMS) containing iron, folic acid, zinc, iodine, vitamins A, D, C, and B-complex vitamins administered daily during pregnancy.

干预措施: Multiple Micronutrient Supplementation (MMS) (Dietary Supplement)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Sher Wali Khan

Research Specialist

Sindh Institute of Child Health and Neonatology

相似试验